Frontline Fall 2021

Page 1



2021, Volume 4

Log in and Learn!

PBCC Virtual Conference to Offer All New Workshops, FREE Nursing Credits


he 2021 PA Breast Cancer Coalition Conference will offer brand new opportunities to learn and connect for women facing breast cancer, caregivers, advocates and our Healthcare Heroes. Participate virtually at your own pace in any location of your choice! Register today for $25 at!

Living with Metastatic presented by Dr. KristenBreast Cancer Fox Chase Cancer CenterWhitaker

FREE for Healthcare Heroes 10 FREE Continuing Ed units Workshop topics include metastatic breast cancer, yoga, genetics, virtual reality, nutrition, breast cancer 101, integrative therapies and more! Reserve your spot today for $25 >>


Sandra Swain, MD, FACP World-renowned researcher

PA Sen. Bob Mensch Legislative Advocate

Lynne Hayes-Freeland

Survivor, KDKA Pittsburgh host

Learn about Dr. Swain’s metastatic breast cancer research on page 6

Jemmi Seeherman Grassroots Partner


“I will NOT miss my mammogram.”

9 mograms during the onset of the COVID-1 Thousands of women canceled their mam a few minutes today and reschedule your pandemic. If you are one of them, please take could save your life. breast cancer screening. It’s a simple step that by ber of breast cancer screenings received The statistics are shocking. The total num and Cervical Cancer Early Detection Program women through the CDC’s National Breast s compared with the previous 5-year average declined by 87 percent in April of 2020 as for that month. or e due to COVID-19? Are you uninsured Have you lost income or health insuranc lable through the PA Department of Health’s underinsured? FREE mammograms are avai on Program (BCCEDP). If you need a free Breast and Cervical Cancer Early Detecti ent Advocacy, Dolores, at 610-622-3390 or mammogram, call our PBCC Director of Pati a 3D mammogram? Visit to find visit Looking for the closest provider. mammogram. Early detection saves lives! Make the call. Mark your calendar. Get your

Send us your videos! We want YOU to be a part of our PBCC Conference Celebrating Survivors and Thrivers session! Take a video of yourself (cell phone works great!) filling in this blank:

“Breast cancer has taught me Upload your videos >>

LYNNE HAYES-FREELAND ALLEGHENY COUNTY How did your breast cancer journey begin? LYNNE: My grandmother was diagnosed with breast cancer in 1920 at the age of 24 and, when my grandmother was diagnosed, it was at a time when people didn’t talk about cancer. They didn’t say it out loud. My grandmother had a double mastectomy and lived to the ripe old age of 96. Later on, I found out that two of her sisters also had breast cancer and my mother was diagnosed with breast cancer, but much later in life at age 77. So, it was always on my radar. I was getting my regular mammograms and then 7 years ago, my sister died of a rare form of appendiceal cancer. My primary care provider recommended I get genetic testing, so I said “let’s go for it” and it came back negative. I had a sigh of relief, but my doctor said that, given my history, I should have alternating mammograms and MRIs every 6 months for the next few years. Six months later, I got an MRI and that’s when my breast cancer was discovered. It was very early, very small, non-aggressive, but it was there. It was a rude awakening for me because I think when you take that genetic test and you’re told you don’t have the gene, you get this sense of “Oh, I’m good,” so I was glad that I listened to my doctor.

Lynne will receive the 2021 Pink Ribbon Award at the PBCC Virtual Conference How have you used your platform as a television and radio host to advocate for others? LYNNE: I had been in the media my entire adult life, but certainly the one thing I’ve always appreciated more than anything is telling stories that impact people or make a difference in somebody’s life. So, when you spend all that time in the media telling stories, your personal stories are often times impactful. About two years ago, it was October - Breast Cancer Awareness Month. I was telling my own story; saying that I had done self exams and that, at the end of the day, you have to advocate for yourself and get your mammograms. The very next day, a woman called in to my show and said, “I was listening to you yesterday, I did my self exam and I felt something. I’m nervous and afraid, but I want to thank you.” She did schedule her mammogram, she did have cancer and it was relatively early. The last I heard from her, she had gone through treatment and was doing fine. You were passionate about the PBCC’s recently passed legislation - Senate Bill 595 for breast ultrasound and MRI coverage. Why was that bill so important to you? LYNNE: I WAS that person who was always told “you have dense breasts.” So, I got that right away. When you have women in newsrooms who also get to look at these potential stories, we get it because we live it. The more you can connect with a story, the more you can convey that message. It outrages me that any woman could ever be in a position to need that screening and not be able to afford it. That angered me and that made me want to follow up on it. Fill in the blank: “Breast cancer has taught me ________”

On her radio show, Lynne stresses the importance of early detection.

LYNNE: Breast cancer has taught me to live in the moment, not taking anything for granted and enjoy every little smile and every little laugh that life has to offer.



Celebrity spouses and volunteers from the Mid Penn Bank Celebrity Golf Tournament for Charity spent a day filling 100 PBCC Friends Like Me Care Packages for newly diagnosed women! The group also packed personal messages inside. Thank you to Mid Penn Bank CEO Rory Ritrievi (right) and to all of the golfers, organizers, volunteers and sponsors for your extraordinary efforts in finding a cure for breast cancer now... so our daughters don’t have to!

finding a cur e now...




4 1. Jim Roberts’ One Lap of America - $4,310 2. Metzger Open - $10,000 3. Armitage Golf Club - $1,453

5 4. WHDGA Golf Tournament - $11,710 5. Golf ‘Til You Drop at Tree Top Golf Course - $6,417 for more GP photos, follow @PABreastCancer on Facebook!


Get your steps in at the 20th Annual Westmoreland Walks Pink Ribbon Walk !



Drive Out Breast Cancer Dealerships across Pennsylvania - proceeds from all sales benefit PBCC! >> Get involved or find a dealership near you at


OCT. 5

PBCC Turns the State Capitol Fountain PINK! State Capitol East Wing Fountain - Harrisburg, PA >> Learn more at

11:00 AM


OCT. 9

Pink Party & PBCC Photo Exhibit (on display Oct. 1-11) Kitchen Kettle Village - Intercourse, PA >> Learn more at


OCT. 16

Westmoreland Walks Pink Ribbon Walk Twin Lakes State Park - Greensburg, PA >> Learn more at

11:00 AM


OCT. 17

Dance for Life Edgewood Country Club - Pittsburgh, PA >> Learn more at


OCT. 18

PBCC Photo Exhibit (on display Oct. 18 - Nov. 1) Millcreek Mall - Erie, PA >> Learn more at

through Nov. 1



The CLEOPATRA Trial and HER2+ Metastatic Breast Cancer Sandra Swain, MD, FACP, FASCO

Associate Dean for Research Development, Georgetown University Medical Center Vice President of Genetic Medicine, MedStar Health

The first results showed a progression-free survival (PFS) benefit of 6 months in those patients who received pertuzumab (PERJETA®) and trastuzumab (HERCEPTIN®) with chemotherapy compared to placebo and trastuzumab with chemotherapy. This large PFS benefit had not been seen before in a HER2 positive metastatic breast cancer study. The CLEOPATRA regimen has become the standard of care worldwide for first line treatment of metastatic HER2 positive breast cancer and is listed specifically in global guidelines. In fact, at the time we were performing the study, the hot drug was TDM1 (KADCYLA®) and was one of the reasons why accrual was so low in the US. There was the thought that pertuzumab was another monoclonal antibody just like trastuzumab and it couldn’t really be better. However, TDM-1 was an antibody drug

conjugate with an exciting new mechanism of action showing activity in the early studies. As it turns out, TDM-1 is now standard of care for second line metastatic breast cancer treatment. Also, recently TDM-1 was approved in the adjuvant setting after neoadjuvant treatment in patients whose tumors did not achieve a pathologic complete response.



ow can I describe the ecstatic feeling I had when I first saw the results of the CLEOPATRA trial? After years of planning, implementing, and overcoming accrual issues, we had finally completed it and had the first results. This was July 2011 and I was among the first to see the results with my colleagues at Genentech. I had hoped, of course, that we would move the needle forward for our patients but had not thought that the outcomes would be so outstanding.

We have made huge advances in metastatic HER2 positive disease. I really think that we can and are working towards the goal of curing these patients.


What is even more exciting is that since the HER2 positive tumors are so sensitive to treatments, a drug specifically benefiting patients with brain metastases has achieved both PFS and overall survival benefits. This drug is tucatinb (TUKSYA®), which is approved in patients who have had 2 lines of HER2 targeted therapy. A second drug antibody

conjugate, trastuzumab deruxtecan (ENHURTU®), has shown fabulous activity with an objective response rate in heavily pretreated patients of 61% in a large phase 2 trial. This has also been approved in patients having received 2 or more HER2 targeted treatments. We have made huge advances in metastatic HER2 positive disease with 37% of patients in the CLEOPATRA study alive at 8 years! And 16.5% of patients were still on study treatment with pertuzumab and trastuzumab at the study closure showing long term outcomes – the question we all have for these patients, are they cured? I certainly hope so and really think that we can and are working towards the goal of curing these patients. At the present time there are over 500 clinical trials evaluating different treatments for HER2 positive disease with some really innovative mechanisms of action and combinations with other targets! In the early breast cancer setting, both trastuzumab and pertuzumab have improved outcomes leading to fewer recurrences. We are seeing more patients who have HER2 metastatic disease present with de novo disease most likely because of the cure in the early breast cancer setting. So, let’s keep moving forward doing very important research to make progress towards a healthier and longer life!





Tuesday, October 5 at 11:00am

Kick off Breast Cancer Awareness Month with the PA Breast Cancer Coalition as we turn the State Capitol East Wing Fountain Pink and celebrate breast cancer survivors! Join us outside the East Wing for FREE Pink Milkshakes from the PA Dairymen’s Association and FREE snacks from Martin’s Chips!

Parking available on Walnut, North and Forster Streets

Will you be there? RSVP


State Capitol East Wing Fountain Commonwealth Ave Harrisburg, PA

2397 Quentin Road, Suite B, Lebanon, PA 17042 800-377-8828

Be a driving force. This October, shop at one of the dealerships dedicated to ending breast cancer.


Virtual Conference Friday, October 15

FREE for Healthcare Heroes and up to 10 FREE CEs for Nurses!